Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

Pfizer, Inc. (NYSE:PFE) shares are trading higher on Tuesday after The Washington Post reported that President Donald Trump will announce a drug-pricing deal with the company. What To Know: According ...

Shares of Pfizer Inc. PFE advanced 1.03% to $25.43 Tuesday, on what proved to be an all-around favorable trading session for ...

After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon ...